AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
10.54
+0.33 (3.23%)
At close: Apr 10, 2026, 4:00 PM EDT
10.49
-0.05 (-0.47%)
After-hours: Apr 10, 2026, 7:04 PM EDT
AgomAb Therapeutics NV Stock Forecast
Stock Price Forecast
The 3 analysts that cover AgomAb Therapeutics NV stock have a consensus rating of "Buy" and an average price target of $32, which forecasts a 203.61% increase in the stock price over the next year. The lowest target is $28 and the highest is $36.
Price Target: $32 (+203.61%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 3, 2026.
Analyst Ratings
The average analyst rating for AgomAb Therapeutics NV stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 |
|---|---|
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $36 | Buy | Initiates | $36 | +241.56% | Mar 3, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $32 | Buy | Initiates | $32 | +203.61% | Mar 3, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $28 | Buy | Initiates | $28 | +165.65% | Mar 3, 2026 |
Financial Forecast
Revenue This Year
1.07M
Revenue Next Year
1.43M
from 1.07M
Increased by 33.33%
EPS This Year
-72.41
from -2.31K
EPS Next Year
-1.63
from -72.41
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.2M | 2.9M | |
| Avg | 1.1M | 1.4M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 174.5% | |
| Avg | - | 33.3% | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.37 | -1.38 | |
| Avg | -72.41 | -1.63 | |
| Low | -136.93 | -1.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.